证券代码：300723 证券简称：一品红 公告编号：2025-053 一品红药业集团股份有限公司 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）第四届监事会第十次会 议于 2025 年 8 月 20 日 15：30 以现场结合通讯表决方式召开。本次会议通知已 于 2025 年 8 月 8 日以电话或电子邮件等方式向全体监事发出。会议由监事会主 席黄良雯女士主持，会议应到监事 3 人，实到监事 3 人，公司高管列席会议。本 次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规以及 《一品红药业集团股份有限公司章程》的有关规定。 二、监事会会议审议情况 1、审议通过《关于<2025 年半年度报告及其摘要>的议案》 监事会认为：公司董事会编制和审核的公司 2025 年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网（http://www ...

证券代码：300723 证券简称：一品红 公告编号：2025-052 一品红药业集团股份有限公司 第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一品红药业集团股份有限公司（以下简称"公司"）第四届董事会第十一次 会议于 2025 年 8 月 20 日 15：00 以现场结合通讯表决方式召开。本次会议通知 已于 2025 年 8 月 8 日以电话或电子邮件等方式向全体董事发出。会议由董事长 李捍雄先生主持，会议应到董事 5 人，实到董事 5 人。公司监事、高管列席会议。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规以 及《一品红药业集团股份有限公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于<2025 年半年度报告及其摘要>的议案》 公司 2025 年半年度报告所载资料内容符合法律、行政法规、中国证券监督 管理委员会和深圳证券交易所的相关规定，报告内容真实、准确、完整，不存在 任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网（http:/ ...

一品红药业集团股份有限公司 2025 年半年度报告全文 证券代码：300723 证券简称：一品红 公告编号：2025-054 一品红药业集团股份有限公司 2025 年半年度报告 2025 年 8 月 1 一品红药业集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人李捍雄、主管会计工作负责人张辉星及会计机构负责人(会计 主管人员)张辉星声明：保证本半年度报告中财务报告的真实、准确、完整。 2.行业政策风险。医药行业受国家相关政策的影响很大，我国正在推进 医药卫生体制改革，相关改革措施的出台和政策的不断完善在促进我国医药 行业有序健康发展的同时，可能会使行业运行模式、产品竞争格局产生较大 的变化，可能给公司带来不确定的风险。面对上述风险，公司将密切关注政 策变化，运用全产业链业务布局的优势与机会积极应对。 3.产品质量风险。药品质量直接关系使用者的生命健康安全，近年来， 药品监管部门对药品质量的监管更为严格。虽然截至目前公司 ...

Group 1 - The A-share market has shown strong upward momentum, with over 60% of doubling stocks being heavily held by public funds [2] - As of August 14, 323 A-shares have doubled in price this year, with 199 of these stocks being heavily held by public funds, indicating a significant interest from institutional investors [2] - Notable doubling stocks include Shenghong Technology, Yipin Hong, Rejing Biology, Shijia Photon, and Yifang Biology, each held by over 50 funds [2] Group 2 - Several doubling stocks saw increased fund buying or further accumulation in Q2, with Shenghong Technology's fund holdings rising from 243 to 454 [2] - The number of doubling funds has also increased significantly, with several funds achieving over 100% net value growth in the past year [3] - Public funds maintain an optimistic outlook for the A-share market, citing a rebound in overall net profit for listed companies despite a decline last year [3] Group 3 - Economic indicators suggest a positive trend, with consumer confidence recovering and real estate market stabilization, supported by new policies [4] - The technology and pharmaceutical sectors are highlighted as key investment areas, driven by AI applications and demographic trends [4] - Investment opportunities are expected to arise in upstream domestic chips and advanced semiconductor processes, as well as advancements in humanoid robotics [4]

Core Insights - The core viewpoint of the news is the performance and holdings of the E Fund Healthcare Industry Mixed A Fund, highlighting its recent returns and key stock positions [1]. Fund Performance - The latest net value of E Fund Healthcare Industry Mixed A is 4.7830 yuan [1]. - The fund has achieved a weekly return of 3.57% [1]. - Over the past three months, the fund's return is 44.07% [1]. - Year-to-date, the fund has generated a return of 57.03% [1]. Fund Details - E Fund Healthcare Industry Mixed A was established on January 28, 2011 [1]. - As of June 30, 2025, the fund's total assets amount to 3.944 billion yuan [1]. - The fund is managed by Yang Zhenshao [1]. Top Holdings - The top ten stock holdings of the fund include: - Heng Rui Medicine - Hotgen Biotech - Xinlitai - BeiGene-U - Haizhi Science - Nocren Health-U - Yipinhong - Kelun Pharmaceutical - Shutaishen - Baili Tianheng [1]. - The combined proportion of the top ten holdings is 58.14% [1].

Group 1 - The chemical pharmaceutical sector increased by 2.34% on August 13, with Shouyao Holdings leading the gains [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] - Notable gainers in the chemical pharmaceutical sector included Shouyao Holdings, which rose by 19.99% to a closing price of 55.94, and Weichip Bio, which increased by 14.39% to 41.18 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 342 million yuan from main funds, while retail investors contributed a net inflow of 426 million yuan [2] - Major stocks with significant net inflows included Heng Rui Pharmaceutical with 55.1 million yuan and Fu Xing Pharmaceutical with 23.4 million yuan [3] - Conversely, stocks like ST Sailong and ST Suwu experienced notable net outflows of 4.97% and 3.70%, respectively [2]

Core Viewpoint - E Fund Healthcare Industry Mixed A Fund (110023) has shown significant performance with a recent net value of 4.5530 CNY, despite a slight decline of 1.73% [1] Performance Summary - The fund's one-month return is 12.81%, ranking 628 out of 4566 in its category [1] - Over the past six months, the fund has achieved a return of 48.74%, ranking 108 out of 4413 [1] - Year-to-date, the fund's return stands at 49.47%, with a ranking of 158 out of 4375 [1] Holdings Summary - The top ten stock holdings of E Fund Healthcare Industry Mixed A account for a total of 58.14%, with the following key positions: - Heng Rui Medicine: 7.39% - Rejing Biology: 7.00% - Xinlitai: 6.73% - BeiGene-U: 6.47% - Haizhi Science: 6.00% - Nocren Health-U: 5.21% - Yipinhong: 5.08% - Kelun Pharmaceutical: 5.07% - Shutaishen: 5.05% - Baili Tianheng: 4.14% [1] Fund Details - E Fund Healthcare Industry Mixed A was established on January 28, 2011, and as of June 30, 2025, it has a total scale of 3.944 billion CNY [1] - The fund manager is Yang Zhenshao, who holds a PhD in Science and has experience as an investment manager, industry researcher, and assistant fund manager at E Fund [1]

金融界消息 截至2025年8月11日收盘，一品红（300723）报收于68.05元，上涨0.06%，换手率1.96%， 成交量8.19万手，成交金额5.58亿元。 天眼查商业履历信息显示，一品红药业集团股份有限公司，成立于2002年，位于广州市，是一家以从事 医药制造业为主的企业。企业注册资本45169.2766万人民币，实缴资本45169.2766万人民币。公司法定 代表人为李捍雄。 通过天眼查大数据分析，一品红药业集团股份有限公司共对外投资了12家企业，参与招投标项目2次， 知识产权方面有商标信息308条，专利信息16条，此外企业还拥有行政许可9个。 来源：金融界 资金流向方面，今日主力资金净流出2079.85万元，占比成交额3.72%。其中，超大单净流出1311.43万 元、占成交额2.35%，大单净流出768.42万元、占成交额1.38%，中单净流出流出408.95万元、占成交额 0.73%，小单净流入2488.80万元、占成交额4.46%。 一品红最新一期业绩显示，截至2025一季报，公司营业总收入3.77亿元、同比减少39.48%，归属净利润 5658.85万元，同比减少43.70%，扣非净利润1 ...

Market Overview - On August 8, the chemical pharmaceutical sector rose by 0.24% compared to the previous trading day, with Lianhuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3635.13, down 0.12%, while the Shenzhen Component Index closed at 11128.67, down 0.26% [1] Stock Performance - Notable declines in individual stocks include: - Shanghai Yizhong: closed at 72.23, down 5.42% with a trading volume of 80,000 shares and a turnover of 573 million yuan - Yifang Bio: closed at 39.80, down 5.37% with a trading volume of 203,000 shares and a turnover of 818 million yuan - Qianhong Pharmaceutical: closed at 10.19, down 4.77% with a trading volume of 1,197,800 shares and a turnover of 1.23 billion yuan [1] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 230 million yuan from institutional investors and a net outflow of 93.16 million yuan from retail investors, while retail investors saw a net inflow of 323 million yuan [1] - Key stocks with significant capital flow include: - Meinuohua: net inflow of 236 million yuan from institutional investors, with a 18.01% share - Lianhuan Pharmaceutical: net inflow of 197 million yuan from institutional investors, with a 13.40% share [2] - Other notable stocks include Han Yu Pharmaceutical and Bo Rui Pharmaceutical, with net inflows of 171 million yuan and 131 million yuan from institutional investors, respectively [2]

Group 1 - The flu concept sector declined by 0.50%, ranking among the top declines in the concept sectors, with companies like Qizheng Tibetan Medicine, New Light Pharmaceutical, and Weikang Pharmaceutical experiencing significant drops [1][2] - Among the flu concept stocks, 56 stocks saw price increases, with Chengyi Pharmaceutical, Kehua Bio, and Guilin Sanjin leading with gains of 10.04%, 10.00%, and 10.00% respectively [1][2] Group 2 - The flu concept sector experienced a net outflow of 2.651 billion yuan, with 116 stocks seeing net outflows, and 11 stocks having outflows exceeding 50 million yuan [2] - The stock with the highest net outflow was Hanyu Pharmaceutical, with a net outflow of 909 million yuan, followed by Tibet Pharmaceutical, Yipinhong, and Zhendong Pharmaceutical [2][3] Group 3 - The top inflow stocks in the flu concept sector included Guilin Sanjin, Borui Pharmaceutical, and Kehua Bio, with net inflows of 948.599 million yuan, 871.114 million yuan, and 772.718 million yuan respectively [2][7] - The overall market performance showed a mixed trend, with various sectors experiencing different levels of gains and losses, indicating a volatile market environment [2][6]